LCN2 and metabolic dysfunction-associated steatotic liver disease: Notably, researchers have identified potential therapeutic targets for improving PCB-induced NAFLD, including the anti-fibrotic compound recombinant FGF21, which reduced the overexpression of hepatic lipocalin-2 (LCN2), a group of transporters of small lipophilic molecules that are upregulated in several liver diseases, and attenuated NAFLD (62, 77).